TITLE

INSULIN Detemir USE IN CHILDREN AGES 2-6 YEARS WITH TYPE 1 DIABETES MELLITUS

AUTHOR(S)
Hasanbegović, Sniježana
PUB. DATE
October 2011
SOURCE
Medical Journal;oct-dec2011, Vol. 17 Issue 4, p315
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Therapy of children with type 1 (T1DM) diabetes mellitus is very complex, especially concerning the treatment of children of preschool age. Conventional insulin due to strict time schedules required meals and activities are related to frequent acute complications (hypo-and hyperglycemia), which leads to variability of blood glucose and poor metabolic control of disease. Insulin analogues can provide insulin pattern most similar to the physiological insulin secretion. Insulin detemir (Levemir) as basal insulin analogue has shown its efficiency in terms of providing good diabetes control with a significantly lower level of hypoglycemia. Successful treatment of diabetes using detemir has also been achieved in the pediatric population. Although detemir by its very action meets the needs of T1DM children aged 2-6 years, lack of valid studies for patients of this age prevented the use of detemir in patients of this age. Current studies done during the last year confirmed the success of treatment of T1DM young children with insulin detemir, with emphasis on its very low affinity for the IGF receptor. As the therapy of patients with T1DM is life-long, besides achieving good metabolic control with less incidence of hypoglycemia, detemir therapy is safe in terms of potential oncogenicity of this insulin analogue.
ACCESSION #
71846143

 

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics